{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:07:13Z","timestamp":1794002833840,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Chimeric Antigen Receptor-T (CAR-T) cell therapy is effective for relapsed\/refractory B-acute lymphoblastic leukemia (r\/r B-ALL) but is not universally available. We developed a novel humanized CD19-directed CAR-T (HCAR19) approved for Phase 1\/1b\/2 trials. Patients aged 3\u201325 years were enrolled with r\/r B-ALL and ineligible for allogeneic stem cell transplant. Lymphodepletion utilized standard-dose fludarabine and cyclophosphamide. A 3\u2009+\u20093 design testing 3 dose-ranges was used to determine Phase-2 Dose (P2D): Dose-A, 1\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> HCAR19 cells\/kg, Dose-B, 3\u20135\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\/kg, and Dose-C, 10\u201315\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\/kg. Primary endpoint was overall response rate (ORR) at day-30 on bone-marrow flow-cytometry. From May-2021 to September-2023 12 patients [median age-14 (range: 5\u201324) years] were enrolled with median bone marrow blasts 19.5% at screening. Cytokine release syndrome occurred in 10 (83%) patients, predominantly Grades 1\u20132, and Grade-2 immune-cell associated neurotoxicity (ICANS) in 1. All patients had Grade-3 cytopenia. ORR was 91.7% (11\/12), complete response (CR) in 8 (66.7%) and partial response in 3 (25%). Seven of 8 CRs were at Dose-levels B and C, all of which were sustained till 12 months follow-up. Patients who received dose levels below 3\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\/kg, or did not achieve CR, had early loss of response or rapid progression. HCAR19 demonstrated safety, manageable toxicity, and durable remissions. and P2D was determined as 5\u201310\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> HCAR19-cells\/kg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial registration<\/jats:title>\n            <jats:p>The study is registered in the Clinical Trials Registry- India (CTRI\/2021\/05\/033348 and CTRI\/2023\/03\/050689).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41408-025-01279-9","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:03:15Z","timestamp":1745467395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel\u2122) cells in relapsed\/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I\/Ib study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-295X","authenticated-orcid":false,"given":"Gaurav","family":"Narula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2834-3868","authenticated-orcid":false,"given":"Swaminathan","family":"Keerthivasagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmukh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-4772","authenticated-orcid":false,"given":"Sachin","family":"Punatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akanksha","family":"Chichra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Dhamne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9030-0415","authenticated-orcid":false,"given":"Prashant","family":"Tembhare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9107-5937","authenticated-orcid":false,"given":"Papagudi Ganesan","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-2857","authenticated-orcid":false,"given":"Nikhil","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Poojary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Gokarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0642-2207","authenticated-orcid":false,"given":"Sumeet","family":"Mirgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albeena","family":"Nisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushali","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atharva","family":"Karulkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankesh Kumar","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aalia","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreshtha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2336-7070","authenticated-orcid":false,"given":"Afrin","family":"Rafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moumita","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juber","family":"Pendhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweety","family":"Asija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambalika","family":"Chowdury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Banik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmalya Roy","family":"Moulik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpushp","family":"Bhosle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumathi","family":"Hiregoudar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingaraj","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayshree","family":"Thorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9754-0182","authenticated-orcid":false,"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3509-5682","authenticated-orcid":false,"given":"Manju","family":"Sengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5708-6472","authenticated-orcid":false,"given":"Navin","family":"Khattry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shripad","family":"Banavali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Highfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3319-0309","authenticated-orcid":false,"given":"Rahul","family":"Purwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"1279_CR1","first-page":"1663","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, Lu X, Devidas M Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group. JClinOncol. 2012;30:1663\u20139.","journal-title":"JClinOncol"},{"key":"1279_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373:1541\u201352.","journal-title":"N Engl J Med"},{"key":"1279_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"CH Pui","year":"2006","unstructured":"Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166.","journal-title":"N Engl J Med"},{"key":"1279_CR4","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/leu.2008.251","volume":"22","author":"K Nguyen","year":"2008","unstructured":"Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, et al. Children\u2019s Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Leukemia. 2008;22:2142\u201350.","journal-title":"Leukemia"},{"key":"1279_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2141.2005.05773.x","volume":"131","author":"PS Gaynon","year":"2005","unstructured":"Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131:579\u201387.","journal-title":"Br J Haematol"},{"key":"1279_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2010.09.020","volume":"47","author":"A von Stackelberg","year":"2011","unstructured":"von Stackelberg A, V\u00f6lzke E, K\u00fchl JS, Seeger K, Schrauder A, Escherich G, et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. Eur J Cancer. 2011;47:90\u20137.","journal-title":"Eur J Cancer"},{"key":"1279_CR7","doi-asserted-by":"publisher","first-page":"LBA","DOI":"10.1182\/blood-2019-132435","volume":"134","author":"PA Brown","year":"2019","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan L, Borowitz MJ, et al. A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR\/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents\/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from Children\u2019s Oncology Group Study AALL1331. Blood. 2019;134:LBA\u20131.","journal-title":"Blood"},{"key":"1279_CR8","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1182\/bloodadvances.2021005579","volume":"6","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, Zugmaier G, Mergen N, Bader P, Jeha S, Schlegel PG, et al. Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood Adv. 2022;6:1004\u201314.","journal-title":"Blood Adv"},{"key":"1279_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u201353.","journal-title":"N Engl J Med"},{"key":"1279_CR10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.21.01693","volume":"40","author":"MM O\u2019Brien","year":"2022","unstructured":"O\u2019Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, et al. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Protocol AALL1621. J Clin Oncol. 2022;40:956\u201367.","journal-title":"J Clin Oncol"},{"key":"1279_CR11","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"1279_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"1279_CR13","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"1279_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14712598.2021.1889510","volume":"21","author":"A Mian","year":"2021","unstructured":"Mian A, Hill BT. Brexucabtagene autoleucel for the treatment of relapsed\/refractory mantle cell lymphoma. Expert Opin Biol Ther. 2021;21:435\u201341.","journal-title":"Expert Opin Biol Ther"},{"key":"1279_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson JrLD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"1279_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991092","volume":"13","author":"E Chekol Abebe","year":"2022","unstructured":"Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, Asmamaw Dejenie T. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol. 2022;13:991092.","journal-title":"Front Immunol"},{"key":"1279_CR17","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.1200\/JCO.2020.38.15_suppl.8039","volume":"38","author":"L Fitzgerald","year":"2020","unstructured":"Fitzgerald L, Kittai A, Nastoupil LJ, Waller A, Jacobson CA, Saucier A, et al. Real-world outcomes of elderly patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy. J Clin Oncol. 2020;38:8039\u201339.","journal-title":"J Clin Oncol"},{"key":"1279_CR18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1182\/blood.2023020197","volume":"142","author":"D Chihara","year":"2023","unstructured":"Chihara D, Liao L, Tkacz J, Franco A, Lewing B, Kilgore KM, et al. Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2023;142:1047\u201355.","journal-title":"Blood"},{"key":"1279_CR19","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/1535-7163.MCT-20-0476","volume":"20","author":"A Dwivedi","year":"2021","unstructured":"Dwivedi A, Karulkar A, Ghosh S, Srinivasan S, Kumbhar BV, Jaiswal AK, et al. Robust antitumor activity and low cytokine production by novel humanized anti-CD19 CAR T cells. Mol Cancer Therapeutics. 2021;20:846\u201358.","journal-title":"Mol Cancer Therapeutics"},{"key":"1279_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol blood marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol blood marrow Transplant"},{"key":"1279_CR21","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1007\/s00277-023-05351-x","volume":"102","author":"N Roy Moulik","year":"2023","unstructured":"Roy Moulik N, Keerthivasagam S, Velagala SV, Gollamudi VR, Agiwale J, Dhamne C, et al. Treating relapsed B cell-precursor ALL in children with a setting-adapted mitoxantrone-based intensive chemotherapy protocol (TMH rALL-18 PROTOCOL)\u2014experience from Tata Memorial Hospital, India. Ann Hematol. 2023;102:2835\u201344.","journal-title":"Ann Hematol"},{"key":"1279_CR22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/08880018.2023.2209158","volume":"40","author":"RS Korrapolu","year":"2023","unstructured":"Korrapolu RS, Boddu D, John R, Antonisamy N, Geevar T, Arunachalam AK, et al. What happens to children with acute lymphoblastic leukemia in low-and middle-income countries after relapse? A single-center experience from India. Pediatr Hematol Oncol. 2023;40:475\u201384.","journal-title":"Pediatr Hematol Oncol"},{"key":"1279_CR23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/cncr.34572","volume":"129","author":"D Espinoza","year":"2023","unstructured":"Espinoza D, Blanco Lopez JG, Vasquez R, Fu L, Mart\u00ednez R, Rodr\u00edguez H, et al. How should childhood acute lymphoblastic leukemia relapses in low\u2010income and middle\u2010income countries be managed: The AHOPCA\u2010ALL study group experience. Cancer. 2023;129:771\u20139.","journal-title":"Cancer"},{"key":"1279_CR24","first-page":"51","volume":"17","author":"A Shibl","year":"2021","unstructured":"Shibl A, Sayed HA, Zahran AM. First relapse of acute lymphoblastic leukemia in children in Upper Egypt: survival outcome and prognostic factors. Res Oncol. 2021;17:51\u20139.","journal-title":"Res Oncol"},{"key":"1279_CR25","first-page":"1876","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood J Am Soc Hematol. 2019;133:1876\u201387.","journal-title":"Blood J Am Soc Hematol"},{"key":"1279_CR26","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021;39:1650.","journal-title":"J Clin Oncol"},{"key":"1279_CR27","first-page":"2361","volume":"134","author":"KJ Curran","year":"2019","unstructured":"Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood. J Am Soc Hematol. 2019;134:2361\u20138.","journal-title":"J Am Soc Hematol"},{"key":"1279_CR28","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","volume":"36","author":"E Jacoby","year":"2022","unstructured":"Jacoby E, Ghorashian S, Vormoor B, De Moerloose B, Bodmer N, Molostova O, et al. CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia. 2022;36:1525\u201332.","journal-title":"Leukemia"},{"key":"1279_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet"},{"key":"1279_CR30","first-page":"3322","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood J Am Soc Hematol 2017;129:3322\u201331.","journal-title":"Blood J Am Soc Hematol"},{"key":"1279_CR31","first-page":"121","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, et al. Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy. Blood J Am Soc Hematol. 2018;131:121\u201330.","journal-title":"Blood J Am Soc Hematol"},{"key":"1279_CR32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/cid\/ciy152","volume":"67","author":"JH Park","year":"2018","unstructured":"Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory b-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clin Infect Dis. 2018;67:533\u201340.","journal-title":"Clin Infect Dis"},{"key":"1279_CR33","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood.2022016937","volume":"141","author":"RM Myers","year":"2023","unstructured":"Myers RM, Shah NN, Pulsipher MA. How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL. Blood. 2023;141:1251\u201364.","journal-title":"Blood"},{"key":"1279_CR34","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/bloodadvances.2023011168","volume":"8","author":"M Gabelli","year":"2024","unstructured":"Gabelli M, Oporto-Espuelas M, Burridge S, Chu J, Farish S, Hedges E, et al. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy. Blood Adv. 2024;8:1959\u201363.","journal-title":"Blood Adv"},{"key":"1279_CR35","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219\u201326.","journal-title":"Cancer Discov"},{"key":"1279_CR36","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1182\/blood-2022-168928","volume":"140","author":"A Karulkar","year":"2022","unstructured":"Karulkar A, Jain H, Shah S, Khan A, Jaiswal A, Firfiray A, et al. Making anti-CD19 CAR-T cell therapy accessible and affordable: first-in-human phase I clinical trial experience from India. Blood. 2022;140:4610\u20131.","journal-title":"Blood"},{"key":"1279_CR37","doi-asserted-by":"publisher","unstructured":"Abou-el-Enein, M., Gauthier, J. The Value of CAR-T-cell Immunotherapy in Cancer. In: Kr\u00f6ger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT\/EHA CAR-T Cell Handbook. Springer, Cham. 2022. https:\/\/doi.org\/10.1007\/978-3-030-94353-0_46.","DOI":"10.1007\/978-3-030-94353-0_46"}],"updated-by":[{"DOI":"10.1038\/s41408-025-01308-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01279-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01279-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01279-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:56:38Z","timestamp":1747806998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01279-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1279"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01279-9","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41408-025-01308-7","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the legend of fig. 3 the colors representing CR and PR have been interchanged. In the Figure, the Green bars correctly represent CR, and the blue bars correctly represent PR. However, in the Legend, the Box against CR has the blue color, and the box adjacent to PR has Green color. The correction needed is to change the colors of these boxes so that the box next to CR shows the Green color and the box next to PR shows the blue color.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41408-025-01308-7","URL":"https:\/\/doi.org\/10.1038\/s41408-025-01308-7","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GN serves as a scientific advisor\/board member in ImmunoACT. HJ has received research and\/or clinical trial support from ImmunoACT, Zydus, and Intas Pharmaceuticals. RP, AK, SS, and AF are equity holders in a private company, have memberships on the entity\u2019s Board of Directors or advisory committees, hold patents and royalties with ImmunoACT, and are currently employed there. JT serves as a consultant for ImmunoACT. NNS is a consultant and\/or advisory board member for ImmunoACT, VOR, Cargo, and Lentigen. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The prospective study was approved by the institutional review boards and ethical committee clearance was obtained (ECR\/149\/Inst\/MH\/2023 and IITB-IEC\/2018\/023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the caretakers of the patients in our study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"75"}}